Abstracts tagged "Antinucleosome antibodies and autoantibodies"

Abstract Number: 2067 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Associated With Inflammatory Myopathy and Other Systemic Autoimmune Rheumatic Diseases In Sera From Breast Cancer Patients
Monica Vázquez-Del Mercado¹, Adrian Daneri-Navarro², Beatriz Teresita Martín-Márquez³, Raul Vargas Ramirez⁴, Diego Velasco-Sanchez⁵, Jason Y.F. Chan⁶, S. John Calise⁷, Edward K.L. Chan⁷ and Minoru Satoh⁶, ¹Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Hospital Civil JIM, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, ²Laboratorio de Inmunología, CUCS, Universidad de Guadalajara, Guadalajara, Mexico, ³Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Guadalajara, Mexico, ⁴CUCS, Universidad de Guadalajara, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético,, Guadalajara, Mexico, ⁵1. Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Mexico, ⁶Medicine, University of Florida, Gainesville, FL, ⁷Oral Biology, University of Florida, Gainesville, FL
Background/Purpose: Various autoantibodies have been reported in cancer patients, however, results are inconsistent. In dermatomyositis (DM), striking association between autoantibodies to p155/140 (transcription intermediary factor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].